AT
Actuate Therapeutics(ACTU)
FORT WORTH, TX
BiotechnologyFocus: Small Molecules for Oncology
Actuate Therapeutics is a life sciences company focused on Small Molecules for Oncology.
Oncology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
9-ING-41
Refractory CancerClinical Trials (1)
NCT042390929-ING-41 in Pediatric Patients With Refractory Malignancies.
Phase 1Retifanlimab
Pancreatic AdenocarcinomaClinical Trials (1)
NCT068961889-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Phase 19-ING-41
CancerClinical Trials (1)
NCT036788839-ING-41 in Patients with Advanced Cancers
Phase 2Gemcitabine
SarcomaClinical Trials (1)
NCT04906876A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Phase 2Ruxolitinib
MyelofibrosisClinical Trials (1)
NCT04218071Actuate 1901: 9-ING-41 in Myelofibrosis
Phase 2Gemcitabine
Soft Tissue SarcomaClinical Trials (1)
NCT05116800Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Phase 2FOLFIRNINOX
Pancreatic AdenocarcinomaClinical Trials (1)
NCT05077800FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Phase 29-ING-41
Salivary Gland CancerClinical Trials (1)
NCT050106299-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Phase 29-ING-41
Pancreatic AdenocarcinomaClinical Trials (1)
NCT052391829-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
Phase 29-ING-41
Salivary Gland CarcinomaClinical Trials (1)
NCT048324389-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 10 clinical trials
SEC Filings: 1 available